Buspirone Does Not Exacerbate Congestive Heart Failure
Buspirone (Buspar) does not exacerbate congestive heart failure and may actually provide benefit in patients with heart failure and central sleep apnea. There is no evidence in the FDA drug label, heart failure guidelines, or medical literature indicating that buspirone worsens heart failure outcomes.
Evidence Supporting Safety in Heart Failure
FDA Drug Label Findings
The FDA-approved prescribing information for buspirone 111 contains no warnings, precautions, or contraindications related to heart failure. The drug label does not list heart failure exacerbation among adverse events, and cardiovascular effects are limited to rare reports of tachycardia/palpitations (1% incidence, same as placebo).
Potential Cardiovascular Benefits
Emerging research suggests buspirone may actually benefit certain heart failure patients. A randomized controlled crossover trial 2 demonstrated that buspirone (15 mg three times daily) in patients with systolic heart failure (LVEF <50%) and central sleep apnea resulted in:
- 41% reduction in CO₂ chemosensitivity
- 42% reduction in apnea-hypopnea index at night
- 79% reduction in central apnea index
- Improved oxygen saturation across 24 hours
- No serious adverse events related to buspirone
This suggests buspirone may improve respiratory parameters in heart failure patients with central apneas, which are associated with worse outcomes.
Important Drug Interactions to Monitor
While buspirone itself doesn't worsen heart failure, be aware of significant drug interactions with medications commonly used in heart failure management:
Diltiazem and Verapamil 1: These calcium channel blockers increase buspirone concentrations 3.4-5.5 fold. If co-administration is necessary, start with low-dose buspirone (2.5 mg twice daily) and titrate based on clinical response. Note that diltiazem and verapamil should generally be avoided in systolic heart failure due to negative inotropic effects 3.
Digoxin 1: Buspirone may displace digoxin from protein binding sites in vitro. Monitor digoxin levels if initiating buspirone in patients on chronic digoxin therapy.
Warfarin 1: One case report documented prolonged prothrombin time when buspirone was added to warfarin therapy. Monitor INR closely if combining these medications.
Clinical Bottom Line
Buspirone is safe to use in patients with congestive heart failure for anxiety management. It does not appear on lists of heart failure-exacerbating medications 4 and carries no heart failure-related warnings in its prescribing information. The primary considerations are drug interactions with common heart failure medications (particularly calcium channel blockers and digoxin) rather than direct cardiac effects.
For patients with heart failure and anxiety requiring pharmacologic treatment, buspirone represents a reasonable option that avoids the negative cardiac effects associated with some other anxiolytics.